BDTX Overview

Analyst Downgrades: JP Morgan downgraded Lennar Corporation from Neutral to Underweight, lowering the price target from $118 to $115, while shares closed at $133.13.

EastGroup Properties: Mizuho downgraded EastGroup Properties from Outperform to Neutral, cutting the price target from $180 to $172, with shares closing at $179.24.

Pentair plc: Barclays downgraded Pentair from Overweight to Equal-Weight, slashing the price target from $127 to $115, as shares closed at $106.47.

PayPal Holdings: JP Morgan downgraded PayPal from Overweight to Neutral, reducing the price target from $85 to $70, with shares closing at $61.24.

Phase 2 Trial Results: Black Diamond Therapeutics reported topline data from its Phase 2 trial of silevertinib in non-small cell lung cancer patients, showing a 60% objective response rate and 86% CNS response rate, with no new safety signals observed.

Stock Performance: Following the trial results, BDTX stock experienced a significant decline of 23.77%, trading at $2.62.

Future Plans: The company plans to present updated trial results in 2026 and is also set to initiate a randomized Phase 2 trial for glioblastoma patients in the first half of 2026.

Financial Outlook: Black Diamond has approximately $135.5 million in cash and investments, which it believes will cover operating expenses into the second half of 2028.

U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones gaining 0.16% while the NASDAQ and S&P 500 fell by 0.42% and 0.07%, respectively. Energy shares rose by 1%, but information technology stocks dropped by 0.9%.

Dollar Tree Earnings Report: Dollar Tree, Inc. reported better-than-expected quarterly results with adjusted earnings per share of $1.21, surpassing the analyst estimate of $1.08, and quarterly sales of $4.746 billion, a 9.4% increase year-over-year.

Significant Stock Movements: Capricor Therapeutics saw a dramatic 441% increase in shares after positive trial results, while CIMG Inc. shares fell 35% following a reverse stock split. Other notable declines included Black Diamond Therapeutics, down 28% after disappointing trial data.

Global Market Trends: European shares mostly rose, with the eurozone's STOXX 600 up 0.2%, while Asian markets closed mixed. Economic indicators showed a decline in the S&P Global services PMI and a slight increase in U.S. industrial production, alongside a job loss of 32,000 in November.